Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Perinatal Depression
Interventions: Dialectical Behavior Therapy (DBT) Skills Training; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Brain Cancer, Glioma
Interventions: 18F-FLT PET Scan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Optical Coherence Tomography of Retina
Interventions: retinal imaging with low-cost OCT device, retinal imaging with commercial OCT device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
Interventions: NST-628; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Hypertension
Interventions: Placebo, ALN-AGT01; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 54
States / cities: Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more

Conditions: Urinary Bladder Neoplasms
Interventions: nivolumab, Placebo, Bacillus Calmette-Guérin (BCG); Drug · Other · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois • The Bronx, New York

Conditions: Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
Interventions: Multidisciplinary Prehabilitation Program; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Rebif® new formulation (RNF); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more

Conditions: High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease
Interventions: high ligation of ileocolic artery, mesenteric sparing; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Stanford, California • Weston, Florida + 1 more

Conditions: High-grade Cervical Intraepithelial Neoplasia
Interventions: Focal LEEP; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Follicular Lymphoma, Lymphoma, Follicular
Interventions: Zevalin Therapeutic Regimen, R-CVP; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Jacksonville, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more

Conditions: Locally Advanced Cervical Cancer
Interventions: Volrustomig, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 15 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more

Conditions: Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
Interventions: LIFE Bronchoscopy; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 85 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hodgkin Lymphoma
Interventions: doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more

Conditions: Type2 Diabetes
Interventions: High Intensity Body-weight Circuit Training (HIBC); Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 45 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Cirrhosis, Hepatocellular Carcinoma
Interventions: Vitamin D; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 3,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 393
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more

Conditions: Breastfeeding, Postpartum Depression
Interventions: Pacifier; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Hours to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myelodysplastic Syndrome, Myelodysplastic Syndromes
Interventions: GSK2879552, Azacitidine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Augusta, Georgia • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions: Campath -1H, Dilantin, Busulfan, Cyclophosphamide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Epilepsy
Interventions: Brain Interchange System; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Search by objective public record fields.

Dialectical Behavior Therapy for Pregnant Women

Image-Guided Stereotactic Biopsy of High Grade Gliomas

Comparative Study of High Performance Low-Cost Optical Coherence Tomography

A Study of NST-628 in Recurrent Grade 4 Glioma

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Prehabilitation in High-risk Oncologic Surgery

Oral Cladribine in Early Multiple Sclerosis (MS)

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

High Intensity Body-weight Circuit Training in Type 2 Diabetics

Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Pacifiers and Breastfeeding Among Mothers at Risk for Postpartum Depression

Moderate to Persistent Asthma in the Obese Subject

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Acute Recording of Stereotyped High-Frequency Oscillations